

11-29-06

ZFW



CASE ON/4-32590A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV727274237 45

Express Mail Label Number

November 28, 2006

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BARANOWSKA-KORTYLEWICZ ET AL.

INTERNATIONAL APPLICATION NO: PCT/IB03/03257

FILED: 17 JULY 2003

U.S. APPLICATION NO: 10/521,299

35 USC §371 DATE: 14 FEBRUARY 2006

FOR: ENHANCING THE EFFECT OF RADIOIMMUNOTHERAPY IN THE
TREATMENT OF TUMORS

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852


Oona A. Jackson
Attorney for Applicants
Reg. No. 48,152

Date: 11/28/06

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32590A
APPLICATION NO.
10/521,299
APPLICANT
BARANOWSKA-KORTYLEWICZ ET
AL.
FILING DATE
February 14, 2006

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 2002/092771	11/21/02	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 2003/037860	05/08/03	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	*Kinuya et al., "Efficacy, Toxicity and Mode of Interaction of Combination Radioimmunotherapy with 5-Fluorouracil in Colon Cancer Xenografts", <i>J Cancer Res Clin Oncol</i> , Vol. 125, No. 11, pp. 630-636 (1999).
	AS	*Le Coutre, "Effects of the Tyrosine Kinase Inhibitor STI571 and Ionizing Radiation on a Human Glioblastoma Cell Line: Potential Use as a Radiosensitizer", <i>Blood</i> , Vol. 98, No. 11, Part 2, p. 179b (2001).
	AT	*Pedley et al., "Eradication of Colorectal Xenografts by Combined Radioimmunotherapy and Combretastatin A-4 3-O-Phosphate", <i>Cancer Res</i> , Vol. 61, No. 12, pp. 4716-4722 (2001).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32590A
APPLICATION NO.
10/521,299
APPLICANT
BARANOWSKA-KORTYLEWICZ ET
AL.
FILING DATE
February 14, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	*Sorokin, "New Agents and Future Directions in Biotherapy", <i>Clin J Oncol Nursing</i> , Vol. 6, No. 1, pp. 19-24 (2002).
	DB	*Wang et al., "Enhancement of the Antitumor Effect of Gamma-ray Irradiation in Combination with Camptothecin Against Human Colorectal Adenocarcinoma", <i>Biol Pharma Bull</i> , Vol. 19, No. 3, pp. 354-359 (1996).
	DC	
	DD	
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.